DIA Biosimilars 2013

Bio-Imaging Technologies

BioClinica Profits Down, Revenues Up Due to Acquisition

Wednesday, May 6, 2009 10:07 AM

BioClinica, the recently renamed and rebranded Bio-Imaging Technologies, reported a 31% drop in profit for the first quarter 2009 compared with the same period last year. Net income decreased from $1.14 million, or $0.09 per diluted share, in 2008, to $786,000, or $0.05 per diluted share, for Q1 2009.

More... »

Cenduit: Now with Patient Reminders

Bio-Imaging to Acquire etrials

Tuesday, May 5, 2009 08:40 AM

Only a week after Bio-Imaging Technologies announced a name change to BioClinica and alluded to future acquisitions, the contract research organization (CRO) announced this morning its intent to acquire troubled eClinical vendor etrials Worldwide.

More... »

CRF Health – eCOA Forum

Bio-Imaging Technologies Changes Name to BioClinica, Expects to Acquire More Companies

Tuesday, April 28, 2009 09:05 AM

Now that Newtown, Pa.-based contract research organization Bio-Imaging Technologies has completed its integration of Phoenix Data Systems, which it acquired in March 2008, the company has changed its name to BioClinica. The new name also marks the start of an active acquisition phase for the 450-employee company, which plans to acquire more companies in the clinical research services space.

More... »

Bio-Imaging Technologies Revenues up 50%

Thursday, February 12, 2009 07:00 AM

Bio-Imaging Technologies reported 50% revenue growth for 2008 following the March 2008 acquisition of Phoenix Data Systems (PDS). Full year 2008 service revenues increased to $56.2 million, up from $37.5 million in 2007. PDS accounted for $12.5 million of that revenue.

More... »

Bio-Imaging Technologies Sells CapMed Division

Thursday, January 8, 2009 09:44 AM

Contract research organization (CRO) Bio-Imaging Technologies has sold off its CapMed division, which provides personal health management solutions to hospitals, employers and pharmaceutical companies, in order to better focus on the CRO’s core clinical trials business.

More... »

Bio-Imaging Q3 Revenues Increase 58%

Friday, November 7, 2008 10:00 AM

Bio-Imaging Technologies saw a big jump in its third quarter revenues thanks to the March 2008 acquisition of eClinical company Phoenix Data Systems (PDS).

More... »

PDS Acquisition Boosts Bio-Imaging Earnings

Thursday, August 21, 2008 02:47 PM

Newtown, Pa.-based contract research organization (CRO) Bio-Imaging Technologies released second quarter financial results that show a 61% increase in service revenues compared with the same period a year ago. Revenues hit $15.2 million for its second quarter compared with $9.5 million for the same period last year. This most recent earnings report reflects the operating results of Bio-Imaging’s March 2008 acquisition of Phoenix Data Systems (PDS). Bio-Imaging’s backlog increased 44.6% to $115.8 million, of which $17.2 million is attributable to PDS. Based on Bio-Imaging Technologies success during the first half of the year, president and chief executive officer Mark Weinstein said the company is increasing its 2008 service revenue guidance to $53 million to $56 million, up from $53 million to $55 million.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs